A calculated risk: Evaluating HIV resistance to the broadly neutralising antibodies10-1074 and 3BNC117

Broadly neutralising antibodies (bNAbs) are a promising new therapy for the treatment of HIV infection. However, the effective use of bNAbs is impacted by the presence of preexisting virological resistance and the potential to develop new resistance during treatment. With several bNAb clinical trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Zacharopoulou, Panagiota, Ansari, M. Azim, Frater, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
THERAPEUTIC VACCINES: Edited by Beatriz Mothe
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594129/
https://www.ncbi.nlm.nih.gov/pubmed/36178770
http://dx.doi.org/10.1097/COH.0000000000000764

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9594129/
https://www.ncbi.nlm.nih.gov/pubmed/36178770
http://dx.doi.org/10.1097/COH.0000000000000764

Ejemplares similares